MA39043B1 - Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs - Google Patents

Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs

Info

Publication number
MA39043B1
MA39043B1 MA39043A MA39043A MA39043B1 MA 39043 B1 MA39043 B1 MA 39043B1 MA 39043 A MA39043 A MA 39043A MA 39043 A MA39043 A MA 39043A MA 39043 B1 MA39043 B1 MA 39043B1
Authority
MA
Morocco
Prior art keywords
treatment
purine derivatives
positions
proliferative disorders
derivatives substituted
Prior art date
Application number
MA39043A
Other languages
English (en)
Other versions
MA39043A1 (fr
Inventor
Douglas Carl Behenna
Hengmiao Cheng
Sujin Cho-Schultz
Jr Theodore Otto Johnson
John Charles Kath
Asako Nagata
Sajiv Krishnan Nair
Simon Paul Planken
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA39043A1 publication Critical patent/MA39043A1/fr
Publication of MA39043B1 publication Critical patent/MA39043B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés de formule (i) ou leur sels pharmaceutiquement acceptables, formule dans laquelle q, g, le cycle a, le cycle b, r1, r2, r3, r4, r5, r5a, r6, r7, r8, r9, r10, r11, r12, r13, r14, r15, r16, r17, r18, r19, r20, r21, r22, r23, r24 et m sont tels que définis dans la description. Ces nouveaux dérivés de purine sont utiles dans le traitement d'une croissance cellulaire anormale, telle que le cancer, chez les mammifères. D'autres modes de réalisation concernent des compositions pharmaceutiques contenant ces composés, ainsi que des procédés d'utilisation de ces composés et compositions dans le traitement d'une croissance cellulaire anormale chez les mammifères.
MA39043A 2013-11-21 2014-11-10 Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs MA39043B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907322P 2013-11-21 2013-11-21
PCT/IB2014/065935 WO2015075598A1 (fr) 2013-11-21 2014-11-10 Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs

Publications (2)

Publication Number Publication Date
MA39043A1 MA39043A1 (fr) 2018-01-31
MA39043B1 true MA39043B1 (fr) 2018-09-28

Family

ID=52004011

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39043A MA39043B1 (fr) 2013-11-21 2014-11-10 Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs

Country Status (39)

Country Link
US (1) US9290496B2 (fr)
EP (1) EP3071570B1 (fr)
JP (2) JP6166845B2 (fr)
KR (1) KR101919672B1 (fr)
CN (1) CN105916853B (fr)
AP (1) AP2016009219A0 (fr)
AR (1) AR098492A1 (fr)
AU (1) AU2014351433B2 (fr)
CA (1) CA2931034C (fr)
CL (1) CL2016001151A1 (fr)
CR (1) CR20160236A (fr)
CU (1) CU24402B1 (fr)
CY (1) CY1120478T1 (fr)
DK (1) DK3071570T3 (fr)
DO (1) DOP2016000115A (fr)
EA (1) EA029842B1 (fr)
ES (1) ES2681799T3 (fr)
GE (2) GEAP201814151A (fr)
GT (1) GT201600091A (fr)
HR (1) HRP20181036T1 (fr)
HU (1) HUE039858T2 (fr)
IL (1) IL245698B (fr)
LT (1) LT3071570T (fr)
MA (1) MA39043B1 (fr)
MD (1) MD20160053A2 (fr)
MX (1) MX2016006397A (fr)
MY (1) MY184433A (fr)
NI (1) NI201600072A (fr)
PE (1) PE20160885A1 (fr)
PH (1) PH12016500911A1 (fr)
PL (1) PL3071570T3 (fr)
PT (1) PT3071570T (fr)
RS (1) RS57537B1 (fr)
SI (1) SI3071570T1 (fr)
TN (1) TN2016000188A1 (fr)
TW (1) TWI538913B (fr)
UA (1) UA115388C2 (fr)
UY (1) UY35845A (fr)
WO (1) WO2015075598A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
KR101879422B1 (ko) 2013-09-18 2018-07-17 베이징 한미 파마슈티컬 컴퍼니 리미티드 Btk 및/또는 jak3 키나제의 활성을 억제하는 화합물
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20180201614A1 (en) * 2015-05-12 2018-07-19 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
US10722515B2 (en) * 2016-09-30 2020-07-28 Sri International Dual CLK/CDK1 inhibitors for cancer treatment
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
AU2018230236B2 (en) 2017-03-10 2022-05-19 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as LRRK2 inhibitors
WO2018163030A1 (fr) 2017-03-10 2018-09-13 Pfizer Inc. Dérivés d'imidazo [4,5-c] quinoléine substitués cycliques
EP3814354B1 (fr) * 2018-06-22 2023-11-08 The Royal Institution for the Advancement of Learning / McGill University Composés de purine et procédé pour letraitement du cancer
WO2020175968A1 (fr) * 2019-02-28 2020-09-03 주식회사 보로노이 Dérivé hétéroaryle contenant de l'azote et composition pharmaceutique le comprenant en tant que principe actif
AU2021276206B2 (en) * 2020-05-20 2024-12-12 Tyk Medicines, Inc. Compound used as RET kinase inhibitor and application thereof
US12115157B2 (en) 2021-09-14 2024-10-15 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US6794390B2 (en) 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
JP3338064B2 (ja) 1997-01-06 2002-10-28 ファイザー・インク 環状スルホン誘導体
NZ336840A (en) 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EP0960098A1 (fr) 1997-02-11 1999-12-01 Pfizer Inc. Derives de l'acide arylsulfonylhydroxamique
JP2002511852A (ja) 1997-05-07 2002-04-16 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
US6255485B1 (en) 1997-08-07 2001-07-03 The Regents Of The University Of California Purine inhibitors of protein kinases, G proteins and polymerases
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
EP1028964A1 (fr) 1997-11-11 2000-08-23 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
SK287132B6 (sk) 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1292591B1 (fr) 2000-06-22 2005-02-02 Pfizer Products Inc. Derives bicycliques substitues destines au traitement de la croissance cellulaire anormale
WO2002022605A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002072549A1 (fr) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Heterocycles fonctionnalises en tant que modulateurs de la fonction du recepteur de chimiokines et procedes de mise en oeuvre
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
EP1578722A4 (fr) 2001-10-12 2006-09-06 Irm Llc Squelettes d'inhibiteurs de kinase et leurs methodes de preparation
US6949644B2 (en) 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
WO2004041285A1 (fr) 2002-10-31 2004-05-21 Amgen Inc. Agents anti-inflammatoires
WO2005016268A2 (fr) 2003-08-08 2005-02-24 Mitochroma Research, Inc. Compositions alimentaires et procedes pour moduler un metabolisme
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
MXPA06001758A (es) 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
GB0502573D0 (en) 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2012791A4 (fr) 2006-02-07 2010-09-22 Conforma Therapeutics Corp 7,9-dihydro-purin-8-one et analogues associés utilisés en tant qu'inhibiteurs de hsp90
EP2008210A1 (fr) 2006-03-15 2008-12-31 Csir Modulation de l'activite phosphoryl transferase de la glutamine synthetase
EP2617423A1 (fr) 2006-10-19 2013-07-24 Genzyme Corporation Dérivés de la purine pour le traitement de maladies kystiques
WO2008057402A2 (fr) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines et composés associés servant d'activateurs de caspases et d'inducteurs d'apoptose et leur utilisation
KR20090112732A (ko) 2007-01-26 2009-10-28 아이알엠 엘엘씨 플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물
US8404674B2 (en) * 2007-03-07 2013-03-26 Boehringer Ingelheim International Gmbh Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
CA2695989A1 (fr) 2007-08-10 2009-02-19 Glaxosmithkline Llc Entites chimiques bicycliques azotees pour traiter les infections virales
BRPI0818578A2 (pt) 2007-10-17 2015-07-21 Novartis Ag Derivados de purina como ligantes receptores de adenosina a1
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
EP2312945A4 (fr) 2008-08-13 2012-05-09 Merck Sharp & Dohme Dérivés de purine pour le traitement de la maladie d alzheimer
TW201024298A (en) * 2008-09-23 2010-07-01 Palau Pharma Sa (R)-3-(N,N-dimethylamino)pyrrolidine derivatives
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010118367A2 (fr) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Pyrimidines antivirales
US9908884B2 (en) * 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
FR2945747A1 (fr) * 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
US20130172340A1 (en) 2010-06-22 2013-07-04 University of Central Flordia Research Foundation, Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
WO2012051587A1 (fr) * 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Méthodes d'inhibition de la prolifération cellulaire dans des cancers induits par l'egfr
WO2012061303A1 (fr) * 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Composés hétéroaryle et leurs utilisations
WO2012064706A1 (fr) * 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Inhibiteurs d'egfr sélectifs d'un mutant et leurs utilisations
EP2704572B1 (fr) * 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Composés permettant d'inhiber la prolifération cellulaire dans les cancers induits par l'egfr
US8762299B1 (en) 2011-06-27 2014-06-24 Google Inc. Customized predictive analytical model training
EP2758402B9 (fr) * 2011-09-22 2016-09-14 Pfizer Inc Dérivés de pyrrolopyrimidine et de purine
CN103159742B (zh) 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
WO2013106792A1 (fr) 2012-01-13 2013-07-18 Acea Biosciences Inc. Composés hétérocycliques et utilisations en tant qu'agents anticancéreux
BR112015023020A2 (pt) 2013-03-14 2017-07-18 Pfizer combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
JP2017214390A (ja) 2017-12-07
TW201524979A (zh) 2015-07-01
EP3071570B1 (fr) 2018-06-20
KR20160077217A (ko) 2016-07-01
CU20160073A7 (es) 2016-10-28
JP6166845B2 (ja) 2017-07-19
HRP20181036T1 (hr) 2018-08-24
CN105916853A (zh) 2016-08-31
MX2016006397A (es) 2016-08-01
US20150141402A1 (en) 2015-05-21
GT201600091A (es) 2017-11-09
MA39043A1 (fr) 2018-01-31
CL2016001151A1 (es) 2017-01-06
EA029842B1 (ru) 2018-05-31
PL3071570T3 (pl) 2018-10-31
ES2681799T3 (es) 2018-09-17
IL245698A0 (en) 2016-08-02
DK3071570T3 (en) 2018-08-13
RS57537B1 (sr) 2018-10-31
MY184433A (en) 2021-04-01
PH12016500911A1 (en) 2016-06-20
MD20160053A2 (ro) 2016-10-31
US9290496B2 (en) 2016-03-22
UY35845A (es) 2015-06-30
JP2016537382A (ja) 2016-12-01
UA115388C2 (uk) 2017-10-25
DOP2016000115A (es) 2016-07-15
AP2016009219A0 (en) 2016-05-31
AR098492A1 (es) 2016-06-01
AU2014351433A1 (en) 2016-06-02
CU24402B1 (es) 2019-05-03
EA201600337A1 (ru) 2016-10-31
SI3071570T1 (sl) 2018-12-31
CA2931034C (fr) 2019-01-08
PE20160885A1 (es) 2016-09-11
CY1120478T1 (el) 2019-07-10
KR101919672B1 (ko) 2018-11-16
GEP20186878B (en) 2018-07-10
LT3071570T (lt) 2018-08-10
EP3071570A1 (fr) 2016-09-28
WO2015075598A1 (fr) 2015-05-28
AU2014351433B2 (en) 2017-08-24
PT3071570T (pt) 2018-08-01
CR20160236A (es) 2016-07-22
IL245698B (en) 2019-11-28
TWI538913B (zh) 2016-06-21
GEAP201814151A (en) 2018-03-26
HUE039858T2 (hu) 2019-02-28
NI201600072A (es) 2016-08-09
TN2016000188A1 (fr) 2017-10-06
CA2931034A1 (fr) 2015-05-28
CN105916853B (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
MA39043A1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
MY161233A (en) Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds
MA35184B1 (fr) Antagonistes de trpv4
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA38240B1 (fr) Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides
MA38287B1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MX2009010225A (es) Nuevos compuestos 707 y sus usos.
MA38009B1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
DE602005014629D1 (de) Pyrazolphenylderivate als ppar-aktivatoren
MA56525B1 (fr) Dérivés de benzisoxazole sulfonamide
MA38591A1 (fr) Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b